anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1\. In the treatment of parkinsonism. Rigidity and tremor relieved by the apparently selective depressant action.   
2\. In the gastrointestinal tract to relieve pylorospasm, hypertonicity of the small intestine and the hypermotility of the colon.   
3\. To relieve hypertonicity of the uterine muscle.   
4\. To relax the spasm of biliary and uretered colic and bronchial spasm.   
5\. To diminish the tone of the detrusor muscle of the urinary bladder in the treatment of urinary tract disorders.   
6\. To control the crying and laughing episodes in patients with brain lesions.   
7\. In cases of closed head injuries which cause acetylcholine to be released or to be present in cerebrospinal fluid which in turn causes abnormal EEG patterns, stupor and neurological signs.   
8\. In the management of peptic ulcer.   
9\. In anesthesia to control excessive salivation and bronchial secretions.   
10\. To control rhinorrhea of acute rhinitis or hay fever.   
11\. As an antidote for pilocarpine, physostigmine, isoflurophate, choline esters, certain species of Aminata and in cases of anticholinesterase insecticide poisoning.   
12\. In poisoning by the organic phosphate cholinesterase inhibitors found in certain insecticides and by chemical warfare “nerve gases”, large doses of atropine relieve the muscarine-like symptoms and some of the central-nervous-system manifestations. Adults suspected of contact with organic phosphorus insecticides of the parathion type should be given atropine sulfate, 0.8 mg, intramuscularly. If an atropine effect is not apparent within thirty minutes or if definite symptoms of the poisoning occur (nausea, vomiting, diarrhea, pupillary constriction, pulmonary edema, fasciculations of eyelids and tongue, jerky ocular movements, and excessive sweating, salivation, and bronchial secretion), atropine sulfate, 2 mg, should be given intramuscularly at hourly intervals until signs of atropinization are observed. Up to two or three times this dose (4 to 6 mg) may be required in severe cases. Removing contaminated clothing, washing the skin, and commencing artificial respiration and supportive therapy are also indicated.
Rhythmic movement disorder (RMD) is a childhood onset sleep disorder that is characterised by repetitive movements that involve large muscle groups, such as body rocking, rolling and head banging. These rhythmic movements are performed prior to and during sleep and as such can disturb sleep with clinical consequences. There is no standard measure to quantify the severity of rhythmic movements. 3D video offers a contactless method of achieving this without disrupting the child's sleep. Vestibular stimulation has a soothing effect and might be effective in promoting sleep. Furthermore, mild vestibular stimulation in the form of gentle rocking movements generated by the Somnomat device might function as a stimulation substitute for the child's RMD with therapeutic potential.

This study aims to a) investigate the feasibility of the detection of episodes of RMD using contactless 3D video analysis and customised analysis software and b) the use of vestibular stimulation as a therapy for childhood rhythmic movement disorder.
Congenital heart disease (CHD) refers to an abnormality in the development of the heart and major blood vessels during fetal development. The prevalence of CHD in China is 8.94 per 1,000 live births and poses a significant public health concern for children's well-being. Infants with CHD often suffer from fluid restriction, nausea, belching, choking and stuttering due to structural changes in the heart and abnormal haemodynamics, which pose a challenge to their nutritional intake. The World Health Organization (WHO) advises that breastfeeding is the best way to nourish infants. Breastfeeding should begin within one hour of birth, and exclusive breastfeeding means that no other food or liquid, including water, should be continued for the first six months of life. The Expert Consensus on Nutritional Support for Children with Congenital Heart Disease recommends breast milk as the optimal nutrition for newborns and encourages infants with CHD to breastfeed. While breastfeeding offers benefits such as immune system enhancement, improved nervous system development, and increased intelligence for infants with CHD, breastfeeding rates are low in this population and interruptions are frequent. A behaviour change program based on the behaviour change wheel will be implemented at the Children's Hospital of Fudan University to enhance breastfeeding behaviour in mothers of infants with CHD, with the aim of increasing the rate of exclusive breastfeeding in this population.
BACKGROUND: Peritoneal fibrosis (PF), a common complication of long-term peritoneal dialysis, accounts for peritoneal ultrafiltration failure to develop into increased mortality. Nintedanib has previously been shown to protect against multi-organ fibrosis, including PF. Unfortunately, the precise molecular mechanism underlying nintedanib in the pathogenesis of PF remains elusive.
METHODS: The mouse model of PF was generated by chlorhexidine gluconate (CG) injection with or without nintedanib administration, either with the simulation for the cell model of PF by constructing high-glucose (HG)-treated human peritoneal mesothelial cells (HPMCs). HE and Masson staining were applied to assess the histopathological changes of peritoneum and collagen deposition. FISH, RT-qPCR, western blot and immunofluorescence were employed to examine distribution or expression of targeted genes. Cell viability was detected using CCK-8 assay. Cell morphology was observed under a microscope. RNA immunoprecipitation (RIP) and chromatin immunoprecipitation (ChIP) assays were applied to validate the H19-EZH2-KLF2 regulatory axis.
RESULTS: Aberrantly overexpressed H19 was observed in both the mouse and cell model of PF, of which knockdown significantly blocked HG-induced mesothelial-to-mesenchymal transition (MMT) of HPMCs. Moreover, loss of H19 further strengthened nintedanib-mediated suppressive effects against MMT process in a mouse model of PF. Mechanistically, H19 could epigenetically repressed KLF2 via recruiting EZH2. Furthermore, TGF-β/Smad pathway was inactivated by nintedanib through mediating H19/KLF2 axis.
CONCLUSION: In summary, nintedanib disrupts MMT process through regulating H19/EZH2/KLF2 axis and TGF-β/Smad pathway, which laid the experimental foundation for nintedanib in the treatment of PF.
The safety of tocilizumab in hospitalized COVID-19 patients was evaluated in a pooled safety population that includes patients enrolled in EMPACTA, COVACTA, AND REMDACTA. The analysis of adverse reactions included a total of 974 patients exposed to tocilizumab. Patients received a single, 60-minute infusion of intravenous tocilizumab 8 mg/kg (maximum dose of 800 mg). If clinical signs or symptoms worsened or did not improve, one additional dose of tocilizumab 8 mg/kg could be administered between 8- 24 hours after the initial dose.

Adverse reactions summarized in Table 3 occurred in at least 3% of tocilizumab -treated patients and more commonly than in patients on placebo in the pooled safety population.

In the pooled safety population, the rates of infection/serious infection events were 30%/19% in patients receiving tocilizumab versus 32%/23% receiving placebo.

Laboratory Abnormalities

In the pooled safety population of EMPACTA, COVACTA, and REMDACTA, neutrophil counts <1000 cells/mcl occurred in 3.4% of patients who received tocilizumab and 0.5% of patients who received placebo. Platelet counts <50,000 cells/mcl occurred in 3.2% of patients who received tocilizumab and 1.5% of patients who received placebo. ALT or AST at or above 5× ULN occurred in 11.7% of patients who received tocilizumab and 9.9% of patients who received placebo.
The Body Project is typically delivered as four 1-hour weekly sessions consisting of written, verbal, and behavioral exercises. The sessions aim to induce cognitive dissonance by encouraging participants to challenge the thin-ideal, a theoretically and empirically supported component of ED prevention. This adapted version of the Body Project (the Pregnant Body Project; PBP) consists of 6 1-hour, weekly group sessions delivered via Zoom. Since the target population consists of individuals with histories of an ED or disordered eating behaviors, PBP also includes elements from a treatment intervention (i.e., the Body Project Treatment 8.0 manual). PBP was adapted iteratively with a needs assessment, expert stakeholder input, and participant feedback following a mock trial with individuals with lived experience (i.e., individuals with histories of an ED who have given birth). This condition will be peer-delivered by facilitators with lived experience.
1. Pharmaceutical tablet constituted by a hydrophilic polymeric matrix permitting controlled and constant release of a unitary therapeutic dose of theophyllin during a period of approximately 12 hours, of the type comprising at least one polymer derived from cellulose and a lubricating agent, characterised in that it contains : . an effective therapeutic quantity of theophyllin ; . from 18% to 35% by weight as a ratio of the total weight of the tablet of at least one hydroxypropylmethylcellulose by way of hydrophyllic polymer, the hydroxypropylmethylcellulose(s) having a viscosity of 2% weight for weight at 20 degrees C between 10**-1 Pa s and 15 Pa .s ; . from 7.5% to 22.5% by weight as a ratio of the total weight of the tablet of lactose favouring hydration of the polymer, and . 0.5% to 1% by weight as a ratio of the total weight of the tablet of an internal hydrophobic lubricating agent, and in that the weight ratio of the theophyllin expressed in anhydrous weight as a ratio to the polymer is between 1 and 3.
The invention relates to a kind of Chinese traditional medicine compound preparation which can treat chronic cholecystitis, its ingredients, extracting technology, preparing technology, function and indication are also disclosed in the invention. The ingredients of the invention include green tangerine peel, Curcuma aromatica, nut grass galingale rhizome, white mustard seed, danshen root, radix astragali and sedi,herba. The preparation in the invention can treat chronic cholecystitis, stagnation of liver-QI with deficiency of the spleen and humid heat heaping. It has the function of dispersing the depressed liver-energy, invigorating the spleen, cholagogue and getting through the collaterals. The preparing procedure of the invention includes the following steps: pulverizing the Chinese traditional medicine properly; steam distillation; enveloping with  beta-cyclodextrin; recirculation with water or alcohol; condensing and drying the extracted solution; adding certain accessories to made pellets, capsules, granules, guttates and other medically acceptable dosages. The advantages of the invention include: sufficient drug sources, simple preparing technologies, obvious curative effect, safe and low toxicity; it's safe and medically reliable.
Chronic subdural hematoma (CSDH) is increasingly common, particularly in the older and multimorbid population. Surgical proficiency in management is required in the early years of U.K. neurosurgical training with most cases performed by nonconsultant-grade surgeons. The aim of this systematic review was to examine the effect of surgeon seniority on recurrence for patients with CSDH. Full-text articles comparing surgical treatment for CSDH with a "senior" (consultant/attending level) or "junior" (resident/registrar or similar) lead surgeon were identified. MEDLine and EMBASE databases were searched. The primary outcome of this study was recurrence. Secondary outcomes included postoperative complications and mortality rate. A random effects meta-analysis was performed. The risk of bias was assessed using the National Institute of Health risk of bias toolkit. Five studies were included in the final analysis (n = 941 total patients). Individually, no study identified a significant difference in recurrence rate and postoperative complications between senior and junior neurosurgeons. On meta-analysis, junior-led evacuations had lower recurrence rates on pooled univariable analysis (12.0% vs. 17.9% [odds ratio 0.48, 95% confidence interval 0.29-0.78, I2 = 0%]) (3 studies). Seniority of surgeon was not associated with increased rates of recurrence patients undergoing CSDH surgery. Complexity of operation may be a confounding factor in observed lower recurrence rates with more junior operators.
Of the 2644 patients who received tocilizumab in Studies I to V [see Clinical Studies (14)], a total of 435 rheumatoid arthritis patients were 65 years of age and older, including 50 patients 75 years and older. The frequency of serious infection among tocilizumab treated subjects 65 years of age and older was higher than those under the age of 65. As there is a higher incidence of infections in the elderly population in general, caution should be used when treating the elderly. 

In the EMPACTA, COVACTA, and REMDACTA studies, of the 974 COVID-19 patients in the tocilizumab arm, 375 (39%) were 65 years of age or older. No overall differences in safety or effectiveness of tocilizumab were observed between patients 65 years of age and older and those under the age of 65 years of age in these studies [see Adverse Reactions (6.5)and Clinical Studies (14.5)] . 

In the RECOVERY study, of the 2022 COVID-19 patients in the tocilizumab arm, 930 (46%) were 65 years of age or older. No overall differences in effectiveness of tocilizumab were observed between patients 65 years of age and older and those under the age 65 years of age in this study [see Clinical Studies (14.5)] .
The anti-allergy composition of the present invention comprises, as an ineffective ingredient, a wood vinegar-distilled solution. A bamboo vinegar-distilled solution obtained using a bamboo as a wood material is preferable. Also, it is preferable that the present composition does not contain benzopyrene, dibenzanthracene, and methylcholanthrene substantially. The anti-allergy composition can exhibit an anti-allergy effect by oral ingestion. In particular, it is useful for inhibiting Type I allergy such as allergic rhinitis, hay fever, allergic conjunctivitis, atopic dermatitis, allergic asthma, urticaria, food allergy, and anaphylaxis. In addition, the composition can be also applied to a skin. When a wood is subjected to smoking treatment at 130 to 170° C., dried, and then carbonized at 350 to 450° C., a smoke discharged during this carbonization treatment is condensed to obtain a crude wood vinegar, and then the crude wood vinegar is distilled at a low temperature of 50 to 60° C. under reduced pressure to obtain a wood vinegar-distilled solution.
The compsn. contains a base gum free from alkaline earth metal, a water-soluble fluorine salt, xylitol and sorbitol. A partic. tablet contains NaF (0.00025g), xylitol (0.867g), sorbitol (0.833g) and an alkaline earth free gum to a total tablet wt. of 2.5g. Sorbitol is used instead of L-sorbase without any change in properties of the compsn. Sorbitol is not fermented by bacterial agents and their enzymes.
BACKGROUND: Obesity is associated with various complications and decreased life expectancy, and substantial heterogeneity in complications and outcomes has been observed. However, the subgroups of obesity have not yet been clearly defined. This study aimed to identify the subgroups of obesity especially those for target of interventions by cluster analysis.
METHODS: In this study, an unsupervised, data-driven cluster analysis of 9,494 individuals with obesity (body mass index ≥ 35 kg/m2) was performed using the data of ICD-10, drug, and medical procedure from the healthcare claims database. The prevalence and clinical characteristics of the complications such as diabetes in each cluster were evaluated using the prescription records. Additionally, renal and life prognoses were compared among the clusters.
RESULTS: We identified seven clusters characterised by different combinations of complications and several complications were observed exclusively in each cluster. Notably, the poorest prognosis was observed in individuals who rarely visited a hospital after being diagnosed with obesity, followed by those with cardiovascular complications and diabetes.
CONCLUSIONS: In this study, we identified seven subgroups of individuals with obesity using population-based data-driven cluster analysis. We clearly demonstrated important target subgroups for intervention as well as a metabolically healthy obesity group.
To provide a hydrolysate of water extract of Java Syzygium jambos which is suitable for whitening of a skin, which can enhance moisture retention of a skin, which can improve wound healing and reduce oxidation stress and a production method thereof.SOLUTION: There is provided a production method of a hydrolysate of water extract of Java Syzygium jambos including a step for extraction processing of a fruit material of JAva Syzygium jambos by water for acquiring water extract, and a step for hydrolysis processing of water extract by bromelain. A weight ratio of the fruit material of Java Syzygium jambos to the water is 1:0.5 to 1:5. A weight ratio of the water extract to bromelain is 150:1 to 600:1. The method further comprises a step for performing solid liquid separation processing after the hydrolysis processing for removing a solid content generated in the hydrolysis processing. The fruit material of the Java Syzygium jambos comprises a pulp of Java Syzygium jambos. The fruit material of the Java Syzygium jambos further comprises a peel of the Java Syzygium jambos and seed of the Java Syzygium jambos.SELECTED DRAWING: Figure 1
BACKGROUND: Peritoneal fibrosis (PF) is the main complication of peritoneal dialysis (PD) and the most common cause of cessation from PD. There is still no effective therapeutic approach to reserve PF. We aimed to investigate the role of miR-132-3p and underlying potential mechanisms in PF.
METHODS: A total of 18 Sprague-Dawley (SD) rats were divided randomly into three groups (n = 6): (i)Control group (ii)PF group (iii)PF+Losartan group; Rats in the PF group and PF+Losartan group received daily intraperitoneal injections of 3 mg/kg chlorhexidine for 14 days, and rats in the PF+Losartan group simultaneously received daily intraperitoneal injections of 2 mg/kg losartan for 14 days. The control group was injected with saline in the same volume. Met-5A cells were treated for 24h with TGF-β1 dissolved in recombinant buffered saline at a concentration of 10 ng/ml, meanwhile, PBS solution as a negative control. The human peritoneal solution was collected for the detection of miR-132-3p.
RESULTS: In vivo, SD rats were infused with chlorhexidine to establish PF model, and we found that miR-132-3p significantly decreased and the expressions of transforming growth factor-β1 (TGF-β1), and Smad2/3 were up-regulated in PF. In vitro, miR-132-3p mimics suppressed TGF-β1/Smad2/3 activity, whereas miR-132-3p inhibition activated the pathway. In human peritoneal solution, we found that the expression of miR-132-3p decreased in a time-dependent model and its effect became more pronounced with longer PD duration.
CONCLUSION: MiR-132-3p ameliorated PF by suppressing TGF-β1/Smad2/3 activity, suggesting that miR-132-3p represented a potential therapeutic approach for PF.
HER2/3 peptide-pulsed DC1 will be administered intrathecally (IT) weekly for 6 doses /cycle for a maximum of two cycles, and then re-staged. If there are sufficient DC1s this may be continued weekly thereafter. There are 1 safety cohort (1 million DCV cells) and 3 escalating doses (2 million, 10 million and 50 million DCV cells) possible.
Rapid genomic testing in critically ill children is becoming the standard of care where there is a high suspicion of an underlying genetic condition and should be provided equitably for all patients in acute care settings. The HGSA encourages an appropriately resourced multidisciplinary team approach, particularly involving genetic health professionals, wherever practicable in the delivery of rapid genomic testing services. Pre-test genetic counselling should be tailored to the family and followup appointments should be offered. Explicit informed consent for rapid genomic testing should be obtained, even in acute care settings. Rapid genomic testing should be delivered with as fast a turnaround time as possible. Laboratories should use genome, rather than exome, sequencing wherever possible. Incidental, secondary findings, and variants of uncertain significance should be reported judiciously. While we recommend the trio approach in this setting, infants or children should not be excluded from rapid genomic testing programmes if one or both biological parents are unavailable.
The invention discloses application of germacrone in preparation of a medicament for treating or preventing influenza viruses. The cell toxicity of the germacrone on madin-darby canine kidney (MDCK) cells is detected, and the result shows that CC50 is more than 250 microns. The influence of the germacrone on the expression of three antigens and the influence of germacrone on virus genome reproduction are detected, and the result shows that the germacrone formulation inhibits the expression of the virus antigens and the virus genome reproduction with dependency. The virus activity resistant mechanism of the germacrone is preliminarily researched. The virus activity resistance stage of the germacrone in a single reproduction period of the influenza viruses is researched by administration experiments of different time, and the result shows that the germacrone has inhibiting effect on adsorption, entry and early reproduction of the viruses. Moreover, the virus activity resistance of the germacrone to amantadine medicament resistant strains, B-type influenza virus strains and A-type influenza virus H3N2 subtype strains is detected, and the result shows that the germacrone has virus activity resistance to the three kinds of virus strains. The germacrone has the effects of relieving cough, relieving asthma and the like.
This clinical trial is an international multi-center prospective clinical registry research, for evaluating the efficacy and safety of Firebird 2 cobalt-chromium alloyed sirolimus-eluting stent in treatment of complex coronary lesions in diabetes. As planned, about 57 research centers all over China, Latin America and Asia-Pacific areas will be involved and, 1300 patients will be enrolled into this research. The implanted stents must all be Firebird2 cobalt-chromium alloyed sirolimus-eluting stent. The patient enrollment will last for 12 months. Clinical follow-up will be done respectively for 30 days, 6 months, 12 months, 18 months, 24 months, 30 months and 36 months. All quitted patients during the study will not be replaced with any substitutes, but categorized in the enrollment failure column. The researcher must state clear the reason of nonenrollment.
Patients will drink citric soda for 7 days. After a washout period of 2 weeks, patients will then drink apple cider vinegar for 7 days.
Participants in the WI arm will take part in the WI program (weeks 3 to 16). After the WI program is completed in week 16, the participants will transition to the physical activity sustainability phase which will include participants having continued access to the information provided during the WI program (weeks 17 to 24).